Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zun Li

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Frontiers in Immunology|November 19, 2025
Functional and clinical validation of tsRNA-defined molecular subtypes guides precision therapy in gastric cancerYe Tian, Xin Hu, Yuan Liu, et al.
Nature Communications|September 3, 2022
Sirtuin 6 maintains epithelial STAT6 activity to support intestinal tuft cell development and type 2 immunityXiwen Xiong, Chenyan Yang, Wei-Qi He, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2011
Discovery of ((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profileRobert O Hughes, D J Rogier, Rajesh Devraj, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Frontiers in Immunology|November 19, 2025
Functional and clinical validation of tsRNA-defined molecular subtypes guides precision therapy in gastric cancerYe Tian, Xin Hu, Yuan Liu, et al.
Nature Communications|September 3, 2022
Sirtuin 6 maintains epithelial STAT6 activity to support intestinal tuft cell development and type 2 immunityXiwen Xiong, Chenyan Yang, Wei-Qi He, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2011
Discovery of ((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profileRobert O Hughes, D J Rogier, Rajesh Devraj, et al.
Pageof 6